Harnessing Insights from GentiBio’s Hypo-Immune Allogeneic Cell Therapy Platform to Advance Allogeneic Cell Therapies
Time: 12:45 pm
day: Conference Day Two Pink Track
Details:
- Explore GNTI-122 autologous Type 1 Diabetes therapy
- Discuss GentiBio’s GNTI-350 hypo-immune allogeneic therapy to uncover key data guiding next-generation autoimmune treatment
- Evaluate the unique characteristics of hypo-immune allogeneic cell therapies over traditional allogeneic approaches
- Apply translational insights to accelerate the progression of allogeneic therapies for autoimmune indications
